Stay updated on Biomarker Response to Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Core study information such as design, eligibility criteria, primary/secondary outcomes, and locations appears unchanged; only formatting and non-substantive details seem updated. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T20:40:49.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    37 days ago
    Change Detected
    Summary
    - Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T04:51:13.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    - Version indicator updated from v3.0.2 to v3.1.0, signaling a new release.
    Difference
    0.1%
    Check dated 2025-09-29T02:55:40.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.
    Difference
    0.2%
    Check dated 2025-09-14T18:53:00.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T13:38:25.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and specific drug information related to various compounds and diseases, while also removing previous mentions of certain drugs and related topics.
    Difference
    5%
    Check dated 2025-08-31T11:35:01.000Z thumbnail image

Stay in the know with updates to Biomarker Response to Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Pembrolizumab in NSCLC Clinical Trial page.